Loxapine - Generic Drug Details

What are the generic drug sources for loxapine and what is the scope of freedom to operate?

Loxapine is the generic ingredient in five branded drugs marketed by Nova Pneuma, Teva Branded Pharm, Actavis Labs Ut Inc, Elite Labs Inc, Lannett Co Inc, Rising, and Watson Labs, and is included in eleven NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Loxapine has twenty-one patent family members in six countries.

There are eight drug master file entries for loxapine.

Summary for loxapine

International Patents:	21
US Patents:	1
Tradenames:	5
Applicants:	7
NDAs:	11
Drug Master File Entries:	8
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	26
Drug Prices:	Drug price trends for loxapine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for loxapine
What excipients (inactive ingredients) are in loxapine?	loxapine excipients list
DailyMed Link:	loxapine at DailyMed

See drug prices for loxapine

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for loxapine

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for loxapine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Strasbourg, France	PHASE2
Assistance Publique - Hôpitaux de Paris	Phase 3
Lariboisière-Saint Louis clinical research unit	Phase 3

See all loxapine clinical trials

Medical Subject Heading (MeSH) Categories for loxapine

Antipsychotic Agents

Dopamine Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for loxapine

N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for loxapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	LOXAPINE SUCCINATE	loxapine succinate	CAPSULE;ORAL	090695-002	Sep 26, 2011	AB	RX	No	No
Teva Branded Pharm	LOXITANE	loxapine succinate	TABLET;ORAL	017525-008	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Teva Branded Pharm	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Elite Labs Inc	LOXAPINE SUCCINATE	loxapine succinate	CAPSULE;ORAL	076868-003	Aug 4, 2005	AB	RX	No	No

Expired US Patents for loxapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012

EU/EMA Drug Approvals for loxapine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Ferrer Internacional S.A.	Adasuve	loxapine	EMEA/H/C/002400Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.	Authorised	no	no	no	2013-02-20

International Patents for loxapine

Country	Patent Number	Title	Estimated Expiration
Japan	2007516403
Canada	2526478	PROCEDE DE REGULATION THERMIQUE UNIFORME D'UN SUBSTRAT ; UNITE DE CHAUFFAGE INTEGREE ET UNITE D'ADMINISTRATION DE MEDICAMENTS RECOURANT A CE PROCEDE (METHODS OF CONTROLLING UNIFORMITY OF SUBSTRATE TEMPERATURE AND SELF-CONTAINED HEATING UNIT AND DRUG-SUPPLY UNIT EMPLOYING SAME)
European Patent Office	1625334	UNITÉ DE CHAUFFAGE AUTONOME ALLUMÉE PAR PERCUSSION (PERCUSSIVELY IGNITED SELF-CONTAINED HEATING UNIT)
Canada	2526475	UNITE DE CHAUFFAGE AUTONOME A ALLUMAGE OPTIQUE OU ELECTRIQUE, ET UNITE D'ADMINISTRATION DE MEDICAMENT UTILISANT CETTE UNITE DE CHAUFFAGE (OPTICALLY IGNITED OR ELECTRICALLY IGNITED SELF-CONTAINED HEATING UNIT AND DRUG-SUPPLY UNIT EMPLOYING SAME)

Supplementary Protection Certificates for loxapine

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1389098	2013C/054	Belgium		PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225
1389098	300609	Netherlands		PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098	SPC/GB13/055	United Kingdom		PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220
1389098	C300609	Netherlands		PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220

Market Dynamics and Financial Trajectory for Loxapine

Last updated: February 13, 2026

Loxapine, a first-generation antipsychotic, primarily treats schizophrenia and agitation associated with psychiatric disorders. Its market emerges within the context of evolving mental health treatment paradigms, clinical competition, regulatory landscape, and patent status.

---

Current Market Size and Revenue

Loxapine's global sales are modest relative to second-generation antipsychotics. Estimated annual revenue for the drug ranges between $50 million and $100 million, driven primarily by legacy formulations. No recent blockbuster status exists, as newer agents with improved safety profiles have gained preference.

Market Drivers

• Therapeutic Relevance: Loxapine remains prescribed for acute agitation, often hospitalized, where rapid tranquilization is essential. Its efficacy in such conditions sustains demand.

• Regulatory Approvals: Approved by the U.S. Food and Drug Administration (FDA) in 1970, its legacy status limits recent approvals. However, the inhaler formulation, approved in 2012 (Adasuve), accessing a niche market for rapid-onset treatment in schizophrenia psychosis, influences demand dynamics.

• Formulation Advancements: The inhaled form offers faster onset and reduced systemic side effects, increasing its appeal in acute care settings.

• Competitive Landscape: Second-generation antipsychotics like risperidone and olanzapine dominate outpatient management, capturing the bulk of prescriptions. The inhaled formulation, with niche applications, faces competition from other rapid-onset agents and benzodiazepines.

Market Challenges

• Side Effect Profile: Extrapyramidal symptoms, sedation, and anticholinergic effects hinder widespread adoption.

• Patent and Exclusivity Status: The original patent expired decades ago; the inhaler formulation's patent protections are limited or near expiry, eroding potential exclusive revenue streams.

• Off-Label Use and Generic Competition: Many formulations are now generic, exerting downward pressure on prices and margins.

• Pricing Pressure: Health systems and insurers increasingly favor cost-effective treatments, limiting revenue growth potential.

Regulatory and Patent Outlook

• The inhaler device patent is set to expire within the next 2–3 years in key markets, opening pathways for generic inhaler products.

• No current pipeline of reformulations or new indications signals limited future regulatory activity.

• Regulatory pathways favoring combination products or new formulations are unlikely without significant investment, which is not currently evident.

Financial Trajectory

• Historical Trends: Revenues have been relatively stable but flat for the past five years, with slight declines expected due to generic competition.

• Forecasts: No significant growth anticipated; markets for the inhaler are saturated, and newer antipsychotics dominate.

• Potential Upside: Limited, unless a new indication or formulation gains approval.

• Downside Risks: Patent expirations, price erosion, and shrinking market share due to advancements in safer, more tolerable agents.

---

Strategic Implications

• Pharmaceutical Companies: Likely to focus on lifecycle management for existing formulations or shift investment toward newer agents.

• Investors: Should consider the drug as a mature asset with declining revenue prospects unless specific niche markets or generics bring new competitive dynamics.

• Healthcare Providers: Continue to use loxapine-based inhalers for rapid-onset scenarios but favor newer therapies for long-term management.

---

Summary

Loxapine's pharmaceutical market operates within a declining trajectory typical of legacy drugs. Revenue stability is maintained mainly through niche applications like rapid-onset inhaled formulations. The upcoming patent expirations and generics threaten pricing power, and competition from newer antipsychotics reduces its market share.

---

Key Takeaways

• Loxapine generates approximately $50–$100 million annually, driven by its inhalation formulation.
• Market growth is limited, with revenues expected decline as patent protections lapse and generics enter.
• Competition from second-generation antipsychotics and safety concerns limit broader adoption.
• Patent expiries for the inhaler device are imminent, pressuring pricing and market exclusivity.
• Future prospects depend on niche application success or reformulation, both unlikely to drive significant growth.

---

FAQs

1. Is loxapine still actively prescribed?
Yes, primarily for acute agitation and hospitalization scenarios; its use is more niche now compared to decades ago.

2. How does the inhaler formulation impact the market?
It provides rapid onset, catering to emergency psychiatric care, but faces patent expiration and competition from other fast-acting agents.

3. What are the main competitors to loxapine?
Second-generation antipsychotics like risperidone and olanzapine, and other rapid-onset treatments such as lorazepam.

4. Will patent expiry significantly affect loxapine revenues?
Yes, it is likely to lead to price erosion and increased generic competition, reducing revenue.

5. Are there ongoing developments to extend loxapine’s market life?
No significant pipeline or reformulation projects are publicly active; market dynamics favor newer therapies.

---

Citations

1. IQVIA. (2022). Pharmaceutical sales analysis.
2. FDA. (2012). Approval of Adasuve (loxapine inhalation aerosol).
3. EvaluatePharma. (2022). Top Selling Drugs.
4. MarketWatch. (2022). Antipsychotics market trends.
5. U.S. Patent Office. (2023). Patent expiration data for inhaler devices.